Darnerud P O, Törnwall U, Bergman A, Brandt I
Department of Toxicology, Uppsala University, Sweden.
Chem Biol Interact. 1993 Dec;89(2-3):89-102. doi: 10.1016/0009-2797(93)90001-f.
The distribution of 2,3,7,8-tetrachloro-[3H]dibenzofuran ([3H]TCDF; 40 micrograms/kg) resembled that earlier reported for 2,3,7,8-tetrachlorodibenzo-p-dioxin, with a strong accumulation in the liver and a selective uptake in the nasal olfactory mucosa of adult and fetal mice. Pretreatments with a series of selected congeners of polychlorinated biphenyls (PCBs), i.e.. I (IUPAC)-77, I-105, I-118, I-126, I-153, I-156, I-169, and a commercial preparation, Aroclor 1254 (25-100 mg/kg body wt. i.p.), were found to modulate the hepatic uptake of [3H]TCDF (24 h post-3H-injection). At a short pretreatment time (4 h), non-ortho-chlorinated congeners decreased the uptake of [3H]TCDF equivalents in the liver (e.g., I-126 = 3,3',4,4',5-pentachlorobiphenyl: 34% of control), while several mono- and di-ortho PCB congeners and Aroclor 1254 increased the hepatic uptake of [3H]TCDF (e.g., I-156 = 2,3,3',4,4',5-hexachlorobiphenyl: 183% of control). At a longer pretreatment time (48 h), both a non-ortho (I-169 = 3,3',4,4',5,5'-hexachlorobiphenyl) and mono-ortho PCB congener(s) (e.g. I-156) markedly increased the hepatic 3H-uptake (190%), a probable effect of an induction of hepatic binding sites for TCDF. Ethoxyresorufin-O-deethylase activities, regarded to mirror the metabolic activity of cytochrome P-450 IA1 (CYP IA1), were strongly and time-dependently induced after I-169, but not after I-156, pretreatment (25 mg/kg). The initial liver concentrations of the two PCB congeners were similar and increased for I-169 but not for I-156 at later time points. In conclusion, the results show a selective uptake of [3H]TCDF in the mouse liver and nasal olfactory mucosa of both dam and fetus. The uptake of [3H]TCDF in the liver is influenced both by dose and pre-exposure with PCBs. The presence of a PCB-sensitive, but CYP IA1-independent, hepatic binding site for TCDF is suggested. Consequently, pharmacokinetic interactions with PCBs complicate the toxicity assessment of TCDF in complex mixtures.
2,3,7,8-四氯-[3H]二苯并呋喃([3H]TCDF;40微克/千克)的分布情况与先前报道的2,3,7,8-四氯二苯并对二噁英相似,在成年和胎鼠的肝脏中大量蓄积,并在鼻嗅黏膜中选择性摄取。用一系列选定的多氯联苯(PCBs)同系物进行预处理,即I(国际纯粹与应用化学联合会)-77、I-105、I-118、I-126、I-153、I-156、I-169,以及一种商业制剂Aroclor 1254(25-100毫克/千克体重,腹腔注射),发现可调节[3H]TCDF(3H注射后24小时)的肝脏摄取。在短时间预处理(4小时)时,非邻位氯化同系物降低了肝脏中[3H]TCDF当量的摄取(例如,I-126 = 3,3',4,4',5-五氯联苯:为对照组的34%),而几种单邻位和二邻位多氯联苯同系物以及Aroclor 1254增加了[3H]TCDF的肝脏摄取(例如,I-156 = 2,3,3',4,4',5-六氯联苯:为对照组的183%)。在较长预处理时间(48小时)时,一种非邻位(I-169 = 3,3',4,4',5,5'-六氯联苯)和单邻位多氯联苯同系物(例如I-156)均显著增加了肝脏对3H的摄取(190%),这可能是诱导了肝脏中TCDF结合位点的结果。乙氧基间苯二酚-O-脱乙基酶活性被认为反映了细胞色素P-450 IA1(CYP IA1)的代谢活性,在I-169预处理(25毫克/千克)后被强烈且随时间依赖性诱导,但在I-156预处理后未被诱导。两种多氯联苯同系物的初始肝脏浓度相似,在后期时间点I-169的浓度增加而I-156的浓度未增加。总之,结果表明[3H]TCDF在母鼠和胎鼠的肝脏及鼻嗅黏膜中选择性摄取。肝脏中[3H]TCDF的摄取受剂量和多氯联苯预先暴露的影响。提示存在一个对多氯联苯敏感但不依赖CYP IA1的肝脏TCDF结合位点。因此,与多氯联苯的药代动力学相互作用使TCDF在复杂混合物中的毒性评估变得复杂。